In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Home-use HIV tests

This article was originally published in The Gray Sheet

Executive Summary

FDA review of Johnson & Johnson's application to market its Confide home HIV sample collection kit appears to be progressing following the review of the policy issues by an agency advisory panel in June ("The Gray Sheet" June 27, p. 6). Senior FDA executives are understood to have alerted the Clinton Administration that the agency sees no policy impediments to approving an over-the-counter HIV test kit. Speaking at a Sept. 19 meeting sponsored by FDA and the Parenteral Drugs Association, FDA Deputy Commissioner Mary Pendergast said that "as far as [FDA is] concerned, home-based collection kits for the HIV virus do not pose major regulatory difficulties if they are accurate and people can get counseling" from professional
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel